Table 3:

Comparison of fluorescence at resection margin and margin pathology for patients with invasive malignancies.

			Following Neoadjuvant Treatment
#	Procedure	Neoadjuvant Treatment	CA19–9 Response*	Tumor Regression on Cross Sectional Imaging	Final Pathology	TBR	Neck Margin Fluorescence	Retroperitoneal Margin Fluorescence	Frozen Section Diagnosis	Final Margin Status
1	PD	None	--	--	PDAC	7.71	Yes	No	N/A	(+) neck, (−) uncinate
2	DP	None	--	--	PDAC	3.77	Yes	No	N/A	(+) neck
3	PD	None	--	--	Intrapancreatic cholangiocarcinoma	2.08	Yes	No	(+) adenocarcinoma	(−)
4	DP	None	--	--	PDAC	12.43	No	No	N/A	(−)
5	PD	None	--	--	PDAC	2.13	No	No	(−)	(−)
7	PD	None	--	--	PDAC	3.29	Yes	No	N/A	(+) neck, (−) uncinate
10	DP	CRT	Yes	Yes	PDAC, 10% viable tumor	1.25	No	No	N/A	(−)
11	DP	No	--	--		4.20	No	No	(−)	(−)
13	DP	CO	Yes	No	PDAC, 100% viable tumor	4.63	No	No	N/A	(−)
13	PD	CO	Yes	No	PDAC, 100% viable tumor	2.76	Yes	No	N/A	(+) neck, (−) uncinate
16	DP	CRT	Yes	Yes	PDAC, 100% viable tumor	4.83	Yes	No	N/A	(+) neck
17	PD	No	--	--	PDAC	3.38	No	No	(+) HGD	(−)
19	PD	CO	No	No	PDAC, 100% viable tumor	5.06	Yes	No	(−)	(−)

* >50% reduction in CA19–9 immediately prior to surgery

Abbreviations: TBR tumor-to-background ratio, PD pancreaticoduodenectomy, PDAC pancreatic ductal adenocarcinoma, DP distal pancreatectomy, CRT chemoradiotherapy, CO chemotherapy only, HGD high grade dysplasia.